This module allows you to explore the tumor expression of some of the immuno-oncological (IO) targets discussed in 
[Cancer Research Institute](href="https://www.cancerresearch.org)
[Clinical Accelerator](https://www.cancerresearch.org/scientists/clinical-accelerator/leadership) publications

- Comprehensive 2017 IO landscape analysis ([Annals of Oncology](https://academic.oup.com/annonc/article/29/1/84/4693829) December 2017)
- Comprehensive 2018 IO landscape analysis including a comparison to the previous year ([Nature Reviews Drug Discovery](https://www.nature.com/articles/nrd.2018.167) October 2018)
- Comprehensive 2019 IO landscape analysis ([Nature Reviews Drug Discovery](https://www.nature.com/articles/d41573-019-00167-9) September 2019)
     
and to connect to additional resources on agents for those targets provided by those studies.
      
All displayed targets and descriptions are compiled and annotated by the 
[Cancer Research Institute](https://www.cancerresearch.org)
[Clinical Accelerator](https://www.cancerresearch.org/scientists/clinical-accelerator/leadership)
management team using publicly available data, including trade news, company press releases, academic publications, and NCBI.
      
For more information about publications and Cancer Research Instituteâ€™s IO Landscape, please go to
[Landscape of Immuno-Oncology Drug Development](https://www.cancerresearch.org/scientists/clinical-accelerator/landscape-of-immuno-oncology-drug-development)
